Ilya Rozenbaum, MD
Ophthalmology · Pennington, NJNPI 1831240704
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,180 of the $3,180 with a category attached, or 68.5%. 18 manufacturers reported payments, led by AbbVie at 39.2% of the total. Reporting peaked in 2022 at $1,570 and has fallen 74.6% since, to $400 in 2025.
Across 55 payments — averaging $57.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$415
- NEW World Medical,inc.$315
- Rxsight Inc$244
- Sight Sciences, Inc.$225
- Ivantis, Inc$129
- plus $605 from 12 others
Across 14 payments — averaging $802.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$11K
What the payments were for
- Consulting fees$1,00031%
- Food & beverage$2,18069%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 4 | $1,247 |
| Alcon | 15 | $415 |
| NEW World Medical,inc. | 3 | $315 |
| Rxsight Inc | 2 | $244 |
| Sight Sciences, Inc. | 7 | $225 |
| Ivantis, Inc | 1 | $129 |
| Bausch & Lomb Americas Inc. | 1 | $107 |
| Eyepoint US, Inc. | 2 | $93 |
| Oyster Point Pharma, Inc. | 1 | $92 |
| Biotissue Holdings Inc. | 4 | $81 |
| Sun Pharmaceutical Industries Inc. | 5 | $75 |
| Shire North American Group Inc | 2 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $29 |
| Novartis | 2 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| Omeros Corporation | 1 | $19 |
| Harrow Eye, LLC | 1 | $17 |
| Quidel Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$1,113
- Kahook Dual Blade$262
- Streamline Surgical System$262
- Ahmed Glaucoma Valve$262
- RXSIGHT CONTACT LENS$244
- RXSIGHT INJECTOR CARTRIDGE$244
- RXSIGHT INJECTOR HANDPIECE$244
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$244
- enVista MX60 IOL$214
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$141
- Hydrus$129
- QULIPTA$122
- UBRELVY$122
- enVista Aspire IOL$107
- OMNI(R) SURGICAL SYSTEM (US)$105
- LIGHT ADJUSTABLE LENS (LAL)$104
How this compares
$3,180 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 231 | $134,856 |
| RhopressaNetarsudil Mesylate | 171 | $84,610 |
| RestasisCyclosporine | 53 | $72,426 |
| CombiganBrimonidine Tartrate/Timolol | 121 | $46,015 |
| Alphagan PBrimonidine Tartrate | 92 | $42,944 |
| Brimonidine Tartrate | 202 | $33,739 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 168 | $32,889 |
| RocklatanNetarsudil Mesylat/Latanoprost | 51 | $27,821 |
| XiidraLifitegrast | 17 | $26,775 |
| Cyclosporine | 26 | $21,081 |
| TyrvayaVarenicline Tartrate | 17 | $20,090 |
| VyzultaLatanoprostene Bunod | 23 | $19,943 |
| Latanoprost | 1,400 | $19,216 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 56 | $16,753 |
| Travoprost | 69 | $13,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,247 | $296,241497 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $107 | $46,71840 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $92 | $20,09017 claims |
| AlconSimbrinza | $415 | $16,75356 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $75 | $8,57312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Pennington
- Cynthia MatossianPennington$655K
- Priya DesaiPennington$10K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.